X-Therma Closes Oversubscribed $13M Series A Financing Led by LOREA AG
Summary
RICHMOND, Calif.--(BUSINESS WIRE)--X-Therma Inc., a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - has closed an oversubscribed $13M Series A funding round. Despite many improvements in surgical techniques and immunosuppression, innovations to extend the time window for safe and reliable organ preservation have, until now, fallen short. From day one, our vision has been focused on the heavy lifting of fundamental scientific breakthroughs to solve the soon-to-be bottlenecks still in existence due to a lack of innovation. X-Therma will also continue to expand its multi-disciplinary team, filling positions remotely (both nationally and internationally) in its San Francisco Bay Area headquarters and Austria subsidiary. X-Therma pioneers ground-breaking cold chain technology via a convergent biopreservation platform, to advance Regenerative Medicine and make available safe and on-demand organs, engineered tissues, cell & gene therapies, vaccines, and beyond to patients in need.